[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618277":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":31,"locations":60,"responsibleParty":89,"collaborators":31,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":95,"sex":101,"minAge":102,"maxAge":31,"enrollmentInfo":103,"targetDuration":31,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":31,"overallStatus":63,"whyStopped":31,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"University of Liege","OTHER",[8,21],{"label":9,"type":10,"description":11,"interventionNames":12},"ICU patients","EXPERIMENTAL","Lab and clinical investigations to characterize the metabolic and muscle profile",[13,14,15,16,17,18,19,20],"Diagnostic Test: Inflammation markers","Diagnostic Test: Blood nucleosomes","Diagnostic Test: Erythrocyte membrane fatty acid content","Diagnostic Test: measurement of myokines","Diagnostic Test: Resting energy expendure","Diagnostic Test: body composition","Diagnostic Test: Omics","Diagnostic Test: Monocyte profile",{"label":22,"type":23,"description":11,"interventionNames":24},"Surgical patients","ACTIVE_COMPARATOR",[13,14,15,16,17,18,19,20],[26,32,36,40,44,48,52,56],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DIAGNOSTIC_TEST","Inflammation markers","measurement of CRP, cytokines, MPO, oxidative stress during the first 7 days after ICU admission, between 1 and 7 days after ICU discharge and 3 months after ICU discharge (or the day after surgery and 3 months after hospital discharge)",[9,22],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Blood nucleosomes","measurement of blood nucleosomes between 1 and 7 days after ICU discharge and 3 months after ICU discharge (or the day after surgery and 3 months after hospital discharge)",[9,22],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Erythrocyte membrane fatty acid content","assessment of Erythrocyte membrane fatty acid content between 1 and 7 days after ICU discharge and 3 months after ICU discharge (or the day after surgery and 3 months after hospital discharge)",[9,22],{"type":27,"name":41,"description":42,"armGroupLabels":43,"otherNames":31},"measurement of myokines","measurement of myokines between 1 and 7 days after ICU discharge and 3 months after ICU discharge (or the day after surgery and 3 months after hospital discharge)",[9,22],{"type":27,"name":45,"description":46,"armGroupLabels":47,"otherNames":31},"Resting energy expendure","assessment of REE by indirect caloriometry during the first 7 days after ICU admission, between 1 and 7 days after ICU discharge and 3 months after ICU discharge (or the day after surgery and 3 months after hospital discharge)",[9,22],{"type":27,"name":49,"description":50,"armGroupLabels":51,"otherNames":31},"body composition","assessment of body composition by BIA during the first 7 days after ICU admission, between 1 and 7 days after ICU discharge and 3 months after ICU discharge (or the day after surgery and 3 months after hospital discharge)",[9,22],{"type":27,"name":53,"description":54,"armGroupLabels":55,"otherNames":31},"Omics","Blood metabolic, lipidomic, proteomic study during the first 7 days after ICU admission (or the day after surgery)",[9,22],{"type":27,"name":57,"description":58,"armGroupLabels":59,"otherNames":31},"Monocyte profile","Blood leukocyte and monocyte profiles and transcriptomic analysis between 1 and 7 days after ICU discharge and 3 months after ICU discharge (or the day after surgery and 3 months after hospital discharge)",[9,22],[61],{"facility":62,"status":63,"city":64,"state":31,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"CHU Sart Tilman","RECRUITING","Liège","4000","Belgium","BE",{"type":69,"coordinates":70},"Point",[71,72],5.56749,50.63373,{"lat":72,"lon":71},[75,80,83,85,87],{"name":76,"role":77,"phone":78,"phoneExt":31,"email":79},"Gwaelle Ducomble","CONTACT","003243237495","gwaelle.ducomble@chuliege.be",{"name":81,"role":82,"phone":31,"phoneExt":31,"email":31},"Damien Wertz, MD","SUB_INVESTIGATOR",{"name":84,"role":82,"phone":31,"phoneExt":31,"email":31},"Bernard Lambermont, PhD",{"name":86,"role":82,"phone":31,"phoneExt":31,"email":31},"Quentin Maloir, MD",{"name":88,"role":82,"phone":31,"phoneExt":31,"email":31},"Grégory Minguet, PhD",{"type":90,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Anne-Françoise Rousseau","Associate Professor","100618277","metabolic-and-muscle-profile-in-icu-survivors-100618277",false,"NCT07329530","Metabolic and Muscle Profile in ICU Survivors","Characterisation of the Inflammatory, Metabolic, and Mitochondrial Profiles in the Context of Post-Intensive Care Muscle Dysfunction","IM3SI","Inclusion Criteria\n\n* Critical illness:\n* anticipated ICU stay \\>= 7 days\n* Major abdominal surgery\n* elective surgery\n\nExclusion Criteria:\n\n* Active malignancy\n* Inherited metabolic disorder\n* Known muscle disease\n* Pregnancy\n* Patient refusal\n* Patient unable to express informed consent (dementia, confusion)\n* Known coagulation disorder (cirrhosis, genetic coagulopathy) or thrombocytopenia \\\u003C 100,000\u002Fmm³ on the day of biopsy, anemia with hemoglobin \\\u003C 9 g\u002FdL on the day of biopsy, or treatment with anticoagulant agents (contraindication to muscle biopsies only)\n* Pacemaker or other implanted electronic device (contraindication to bioelectrical impedance analysis only)\n* Oxygen therapy (contraindication to indirect calorimetry during spontaneous ventilation)","ALL","18 Years",{"count":104,"type":105},100,"ESTIMATED","INTERVENTIONAL",[108],"NA","More and more patients survive a critical illness requiring admission to the intensive care unit, but they may be left with sequelae that are independent of the initial pathology. From a physical standpoint, the most visible complication is intensive care unit-acquired muscle weakness. A major factor in the development and persistence of muscle dysfunction appears to be the inflammatory response and the neuroendocrine stress response triggered by the initial critical insult. Persistence of inflammation beyond ICU discharge has been demonstrated in several studies. In response to inflammation, there is also increased oxidative stress associated with mitochondrial dysfunction.\n\nThe objectives of the present study are therefore:\n\nto determine whether the broad inflammatory and metabolic profile of patients who have survived an ICU stay can predict the trajectory of muscle performance over the three months following ICU discharge; to compare this profile and muscle performance with those of non-critically ill surgical patients who have undergone a standardized inflammatory stress of lower intensity than that associated with critical illness; to investigate mitochondrial function in skeletal striated muscle after ICU stay, in light of the inflammatory and metabolic profile; to assess whether abnormalities in mitochondrial function also affect tissues other than skeletal muscle, in particular circulating blood mononuclear cells.",[111,112],"Critical Illness","Major Abdominal Surgeries","2026-01-08",{"date":115,"type":116},"2026-01-12","ACTUAL",{"date":118,"type":116},"2025-12-01",{"date":120,"type":105},"2029-04-01",{"name":91,"class":6},1]